Cargando…

Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer

Prostate cancer (PCa) growth and progression rely on the interaction between the androgen receptor (AR) and the testicular ligands, testosterone and dihydrotestosterone (DHT). Almost all men with advanced PCa receive androgen deprivation therapy (ADT). ADT lowers circulating testosterone levels, whi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fiandalo, Michael V., Gewirth, Daniel T., Mohler, James L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Second Military Medical University 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363635/ https://www.ncbi.nlm.nih.gov/pubmed/30775248 http://dx.doi.org/10.1016/j.ajur.2018.09.002

Ejemplares similares

A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)
por: LACY, JOHN M., et al.
Publicado: (2014)

Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment
por: Fiandalo, Michael V., et al.
Publicado: (2014)

The impact of finasteride and dutasteride treatments on proliferation, apoptosis, androgen receptor, 5α-reductase 1 and 5α-reductase 2 in TRAMP mouse prostates
por: Opoku-Acheampong, Alexander B., et al.
Publicado: (2017)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α(β)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells
por: Wiebe, John P, et al.
Publicado: (2003)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Current Status of 5α-Reductase Inhibitors in Prostate Disease Management
por: Kang, Dong Il, et al.
Publicado: (2013)

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Inhibition of α-glucosidase, α-amylase, and aldose reductase by potato polyphenolic compounds
por: Kalita, Diganta, et al.
Publicado: (2018)

A Multiscale, Mechanism-Driven, Dynamic Model for the Effects of 5α-Reductase Inhibition on Prostate Maintenance
por: Zager, Michael G., et al.
Publicado: (2012)

5α-reductase inhibitors impact prognosis of urothelial carcinoma
por: Wang, Chien-Sheng, et al.
Publicado: (2020)

Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
por: Busato, Wilson F. S.
Publicado: (2020)

Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention
por: Li, Jin, et al.
Publicado: (2011)

Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade
por: Fiandalo, Michael V., et al.
Publicado: (2018)

Hypothesis on Serenoa repens (Bartram) small extract inhibition of prostatic 5α-reductase through an in silico approach on 5β-reductase x-ray structure
por: Governa, Paolo, et al.
Publicado: (2016)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
por: Kumar, Abhishek, et al.
Publicado: (2019)

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
por: Ong, Hueih Ling, et al.
Publicado: (2016)

Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer
por: Bhattacharjee, Biplab, et al.
Publicado: (2011)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man
por: Hazlehurst, Jonathan M., et al.
Publicado: (2016)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

Combined effect of polymorphisms in type III 5-α reductase and androgen receptor gene with the risk of benign prostatic hyperplasia in Korea
por: Lee, Chung Lyul, et al.
Publicado: (2016)

5‐α reductase inhibition by Epilobioum fleischeri extract modulates facial microbiota structure
por: Sfriso, Riccardo, et al.
Publicado: (2022)

Hydrogen sulfide stimulates xanthine oxidoreductase conversion to nitrite reductase and formation of NO
por: Pardue, Sibile, et al.
Publicado: (2020)

Is There a Link between 5α-Reductase Inhibitors and Hypoglycemia?
por: Jeong, Jin Woo, et al.
Publicado: (2021)

Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Protective Role of 4-(4-Hydroxy-3-methoxyphenyl)-2-Butanone on Prostatic Cells Hyperplasia of Rats and Human, 5α-reductase Inhibition Pathway
por: Ahmed, Ahmed S., et al.
Publicado: (2021)

Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5α- reductase type 2 and induced cell apoptosis
por: Karunasagara, Shanika, et al.
Publicado: (2020)

Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate
por: Castro, Beatriz, et al.
Publicado: (2013)

Bisphenol A Modifies the Regulation Exerted by Testosterone on 5α-Reductase Isozymes in Ventral Prostate of Adult Rats
por: Sánchez, Pilar, et al.
Publicado: (2013)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
por: Liu, Zhanliang, et al.
Publicado: (2022)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy
por: Heo, Ji Eun, et al.
Publicado: (2018)

Evidence for an Association between the SRD5A2 (Type II Steroid 5α-Reductase) Locus and Prostate Cancer in Italian Patients
por: Margiotti, K., et al.
Publicado: (2000)

Relative adrenal insufficiency in mice deficient in 5α-reductase 1
por: Livingstone, Dawn E W, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2osjucj470s18ov89renljcd0j